The report is available here http://cellink.com/investor-relations/. This press release presents a summary of the report.

First 9 months, September 1st, 2017 – May 31st, 2018

  • Operating revenues amounted to 39,724 kSEK (12,750 kSEK), an increase of 212% against the previous fiscal year
  • Net sales of 28,656 kSEK (SEK 8 465 thousand), an increase of 239% against the previous financial year
  • Operating profit before depreciation, EBITDA amounted to 1 914 kSEK which corresponds to an EBITDA margin of 4.8% (-8,0%)
  • Operating profit amounted to -88 kSEK (-1 205 kSEK)
  • Profit before tax amounted to 414 kSEK (-1 319 kSEK)
  • Earnings per share amounted to 0,00 SEK for the first 9 months (-0,20 SEK)
  • Cash flow from operating activities in the period amounted to -4 534 kSEK (-389 kSEK)

Third quarter (Q3), March 1st, 2018 – May 31st, 2018

  • Operating revenues amounted to 16,375 kSEK (4,876 kSEK), an increase of 236% against the previous fiscal year
  • Net sales of 12,202 kSEK (SEK 3 024 thousand), an increase of 304% against Q3 the previous financial year
  • Operating profit before depreciation, EBITDA amounted to 1 044 kSEK which corresponds to an EBITDA margin of 6.4% (-20,7%)
  • Operating profit amounted to 399kSEK (-1 105 kSEK)
  • Profit before tax amounted to 626 kSEK (-1 139 kSEK)
  • Earnings per share amounted to 0,048 SEK in the 3rd quarter (-0,17 SEK)
  • Cash flow from operating activities in the quarter amounted to -1 202 kSEK (-2 581 kSEK)

Significant events during the period 

Events in the third quarter (March 2018 – May 2018) 

  • March 19, CELLINK published an article on Bioink together with researchers, the article was published in Bioprinting which was about the different characters of bioinks
  • April 9, CELLINK won RED DOT AWARD FOR BIO X
  • April 13, CELLINK launches 7 new Bioinks, 3 new kits with GelMA, and enables 3D bioprinting of multi-faceted vascular networks
  • April 19, CELLINK joined ARMI BioFab USA, UNH Manchester for Regenerative Production Event
  • April 23, CELLINK Carnegie Investment Bank AB (publ) appointed financial adviser
  • May 2, CELLINK launched a new educational platform for bioprinting: CELLINK GO – designed to revolutionize education
  • May 3 CELLINK changed Certified Adviser to Erik Penser Bank AB
  • May 4, CELLINK published news about partners that 3D Bioprint Human Cardiovascular Disease Models with Nano-Density Biomechanics
  • May 11, CELLINK received an order of MSEK 3.5 from distributor in Germany

Events after the end of the period

  • June 1, CELLINK published news about customer and technology users at Newcastle University 3D Bioprinting first human corneas in pioneering breakthrough
  • June 4, CELLINK executed a directed new issue of SEK 100,259,570

Events in the first 9 months (September 2017 – May 2018)

  • September 25, CELLINK was granted design patent for the BIO X product
  • September 27, CELLINK announced a collaboration agreement with the Massachusetts Institute of Technology
  • On 6 October, a directed new issue of SEK 30 million was made to Handelsbanken Fonder
  • November 15, CELLINK announced a development cooperation with Takara Bio
  • On November 27, the company announced that they had been granted project funding from the EU
  • January 8, the company announced a cooperation agreement with CTIBIOTECH to print human cancer tumor tissues
  • January 17, the company announced the establishment of a research and development laboratory in AstraZeneca’s BioVentureHub
  • February 1, CELLINK announced the opening of an office at Kyoto University in Japan
  • February 8, CELLINK announced launching CELLINK X Bioinks
  • March 19th, CELLINK published an article on Bioinks together with researchers, the article was published in Bioprinting which was about the different characters of bioinks
  • April 9, CELLINK won Red Dot Award for BIO X
  • April 13, CELLINK launched 7 new Bioinks, 3 new kits with GelMA, and enables 3D bioprinting of multi-faceted vascular networks
  • April 19, CELLINK joined ARMI BioFab USA, UNH Manchester for Regenerative Production Event
  • April 23 CELLINK appointed Carnegie Investment Bank AB (publ) to financial adviser
  • May 2, CELLINK launched a new educational platform for bioprinting: CELLINK GO – Intended to Revolutionize Education
  • May 3rd change CELLINK Certified Adviser to Erik Penser Bank AB
  • May 4th, CELLINK published news about a collaborator that 3D-Bioprinted Human Heart Disease Models with Nano-Density Biomechanics
  • May 11, CELLINK received an order of MSEK 3.5 from a distributor

For further information, please contact:

Erik Gatenholm, CEO                                      Gusten Danielsson, CFO

Phone: +46 73 267 00 00                              Phone: +46 70 991 86 04

E-mail: eg@cellink.com                                E-mail: gd@cellink.com

Important information

This information is such information as CELLINK AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on July 11, 2018 at. 08:30 CET.

About CELLINK

CELLINK has created one of the world’s first universal Bioinks, today used by many of the world’s most well-reputed research institutions. A Bioink can be mixed with living cells to print functional human tissues and if future research is successful, eventually, complete human organs in so-called 3D-Bioprinters. CELLINK’s universal Bioink shows excellent results and can be used in both CELLINK’s proprietary 3D Bioprinters and in 3D Bioprinters developed by other operators. Erik Penser Bank AB is the company’s Certified Adviser, available on tel: +46 8 463 80 00. The company is listed on Nasdaq First North under CLNK.